Peptide Therapy CJC-1295
Provider evaluation · Appropriate testing · Ongoing monitoring
One Compound, Fewer Injections, Not A Different Result
CJC-1295 is a growth-hormone-releasing hormone analog, engineered to stay active in the body longer than shorter-acting peptides in the same category. Patients ask about it for 3 reasons: wanting the recovery and sleep benefits associated with growth hormone support, wanting fewer weekly injections than other GHRH peptides require, and wanting a more stable, sustained release rather than a single daily spike. CJC-1295 is not a stronger version of sermorelin or ipamorelin, and it is not a shortcut around evaluation and monitoring. It appears to extend how long growth hormone release stays elevated after a single dose, which is a convenience and consistency difference, not a different mechanism entirely. At T Clinics USA, CJC-1295 is prescribed after an evaluation and lab work, and it is frequently paired with other compounds rather than used alone. Your provider determines whether it, another growth hormone peptide, or a combination best fits your labs and goals.
What You Get Beyond The Prescription
CJC-1295 works inside a plan, not on its own. Here is what that plan looks like at T Clinics USA in Naples, Fort Myers, and Coral Springs.
How It Works
How CJC-1295 Is Used at T Clinics USA
You have questions, we have answers.
Where CJC-1295 Stands Today
CJC-1295 is not FDA-approved. It is prescribed as a compounded medication, and compounded medications are not FDA-approved. We tell patients this directly rather than describing it as a settled, approved treatment.






